T reatment strategies for inflammatory bowel disease (IBD) have evolved toward earlier use of biological agents alone 1 and in combination with traditional immunomodulators [1] [2] [3] in properly selected patients. 4 With the introduction of antiintegrin therapies 5 and the already large stable of biological agents targeting tumor necrosis factor (TNF), 6, 7 the need for providers to engage in a comprehensive discussion about the relative benefits and risks of each therapy is becoming even more acute. 8 The risk for serious infection with biological agents is well described, [9] [10] [11] and current guidelines recommend appropriate prescreening to detect at-risk patients. [12] [13] [14] [15] However, the risk for any infection with biological agents has not been well evaluated in the literature. Common infections that are generally tolerated in the general population might be more severe in patients who are immunosuppressed by IBD therapy, and milder primary infections might lead to potentially serious secondary infections. 16, 17 Infections of any severity can undermine long-term treatment adherence 18 and thus affect durability of therapy. Indeed, delays or lapses in biological therapy use in patients with IBD can result in potentially poorer outcomes 19 and higher costs of care. 20, 21 Considering the role that assessment of risk:benefit analysis plays in selecting an optimal therapy for patients with IBD, 22 we sought to evaluate the risk for any infection with available biological agents used in IBD by analyzing data from published randomized, placebo-controlled trials of patients with moderateto-severe Crohn's disease (CD) and ulcerative colitis (UC).
METHODS
We conducted a systematic review and meta-analysis based on the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) statement. 23 Biological therapies identified for analysis received at least a grade B rating from relevant North American and European guidelines and had evaluated at least 50 patients in pooled trials. Peer-reviewed, double-blind, placebo-controlled randomized trials were systematically identified using a literature search with PubMed and the Cochrane Library (May 5, 2015 until August 13, 2016). The search algorithm was as follows: {"Crohn Disease"(Mesh) AND (adalimumab OR infliximab OR certolizumab OR natalizumab OR vedolizumab) AND ("trial" or "trials" or "Clinical Trial"[ptyp]) AND Randomized Controlled Trial[ptyp]}; ("Colitis, Ulcerative" [Mesh] or "ulcerative colitis") AND (adalimumab OR infliximab OR certolizumab OR golimumab OR vedolizumab OR MLN02) AND ("trial" or "trials" or "Clinical Trial" [ptyp] ). All abstracts from search results were reviewed against a priori inclusion criteria (Table 1) . We included all studies regardless of language and translated eligible studies to English language when needed.
Data Extraction
Data were extracted regarding disease of interest, location of study, phase of study, number of study centers, eligibility criteria, screening protocol when applicable, study length and trial protocol, allowable and disallowed concomitant therapy and history of medication use, protocol for rescue therapy, and trial endpoints. Trials were stratified based on their evaluation of maintenance therapy or combined induction and maintenance therapy. Data were extracted based on the safety population when available; otherwise, the intention-to-treat population was used. Primary data were extracted independently by authors E.D.S. and J.F. using a standardized data extraction table using Microsoft Excel 2010 (Redmond, WA) and reviewed for accuracy by E.D.S. and J.F. Discrepancies in data were reviewed and rectified by consensus among authors.
Primary and Secondary Endpoints
The primary endpoint was the relative risk (RR) of harm based on the overall occurrence of any infection reported as an adverse event relative to placebo. Number needed to harm (NNH) due to infection, with harm defined as occurrence of any infection, was calculated when the RR for harm was statistically significant. There were 2 secondary endpoints. The first secondary endpoint was ascertainment of the types of infection for which patients are at greatest risk. Given that nomenclature for common infection can vary from study to study (such as pharyngitis versus upper respiratory infection), we set out to organize specific infections by the anatomy affected (such as upper versuslower respiratory tract). Within these types of infection, we classified infections as serious if they required intravenous antibiotics, hospitalization, or resulted in death.
The second secondary objective was to determine the risk of opportunistic infections, defined by any infection deemed opportunistic by study authors and infections such as Candida, Aspergillus, Mycobacterium tuberculosis, varicella zoster virus, Cytomegalovirus, Pneumocystis jirovecii, JC virus, herpes simplex, Epstein-Barr virus, and Legionella.
Statistical Analysis
Statistical analysis was performed using a DerSimonian and Laird random-effects model of meta-analysis to determine RR for harm because of infection. This model was chosen as it conservatively accounts for unmeasurable differences in study design and differences among study centers and populations. When cell counts equaled zero, we replaced cells in the relevant 2 · 2 table using a proportional continuity correction method, to reduce bias attributed to unbalanced treatment groups in the setting of rare events. 24 RR was calculated and displayed with forest plots, and a chi-square test of significance was performed. NNH was calculated when the RR for harm was statistically significant. Publication bias and study heterogeneity were assessed using modified Egger plots and I 2 analysis, respectively.
We applied the risk of bias methodology using the Cochrane risk of bias tool to assess study quality. This methodology applies scrutiny toward the randomization protocol and concealment of therapy, presence of blinding among parties, study attrition and completeness of outcome data, and presence of selective reporting of each study.
We provided summary tabulation of infections for which patients are at the greatest risk; however, no statistical analysis was performed to evaluate specific types of infection.
TABLE 1. Study Eligibility Criteria

Inclusion criteria
Maintenance or combined induction/maintenance placebo-controlled randomized clinical trial for a specified period of at least 20 wk duration Evaluation of a single investigational agent in each active study arm A priori definitions of moderate-to-severe or steroid-dependent CD or UC, active CD or UC, and clinical remission Administration of .1 dose of study agent or placebo during length of trial Evaluation and reporting of a remission outcome and adverse events including infection Exclusion criteria Evaluation limited to discontinuation of investigational therapy Thresholds to initiate rescue therapy were not prespecified Evaluation limited to fistulizing or postsurgical CD FIGURE 1. Flowchart of study inclusion. 
RESULTS
Fourteen trials of biological therapies (8 in CD and 6 in UC) were deemed eligible for our analysis (Fig. 1) . The CD trials comprised 2013 patients enrolled in 6 anti-TNF trials (infliximab, 25 adalimumab, [26] [27] [28] [29] and certolizumab 30 ) and 889 patients enrolled in 2 anti-integrin trials (natalizumab 7 and vedolizumab 31 ). The UC trials comprised 1832 patients enrolled in 5 anti-TNF trials (infliximab, 32, 33 adalimumab, 34 and golimumab 35 ) and 373 patients in one anti-integrin trial of vedolizumab. 36 A summary of these studies is shown in Table 2 with corresponding rates of any infection, opportunistic infection, and serious infection in Table 3 . Interobserver reliability of infection rates resulted in a Cohen's kappa statistic of 1.0. The I 2 statistic regarding study heterogeneity is reported for each in Figure 2 . There was no significant publication bias in any analysis using Harbord's test with the exception of infliximab in combined induction and maintenance for UC (P ¼ 0.019).
Overall Risk for Infection
The RR for infection for individual and pooled therapy is detailed in Table 4 . Relevant forest plots are shown in Figure 2 .
All 6 eligible CD trials of anti-TNF agents [25] [26] [27] [28] [29] [30] assessed maintenance of remission. In the pooled analysis of anti-TNF agents, the RR for overall infection was not statistically significant. In fact, patients who remained on maintenance infliximab through the entirety of the trial were less likely to develop infection than were those switched from active therapy to placebo. 25 There was evidence of significant study heterogeneity (I 2 ¼ 78%) (Fig. 2) .
For anti-TNF agents in UC, the one maintenance trial evaluating golimumab 35 
There were 2 maintenance trials evaluating anti-integrin agents in CD. 7, 31 Neither agent was associated with a statistically significant risk for infection. Pooled analysis of both trials also revealed no statistically significant risk for infection.
Vedolizumab as UC maintenance therapy 36 did not result in statistically significant RR for infection in patients on active treatment.
Specific Infections as Adverse Events
The most common infection in excess of placebo across all agents in both CD and UC was upper respiratory infection. Adverse events numerically in excess of placebo are summarized in Table 5 . Because of heterogeneity in reporting and classification of specific adverse events, statistical analysis was not performed.
Opportunistic Infections
Opportunistic infections were numerically more common with both anti-TNF and anti-integrin therapies relative to placebo in pooled trials, but the RR for opportunistic infection was not significantly higher than that of placebo. The rate of opportunistic infection in patients on anti-TNF therapy was 0.9% (23/2332 patients) versus 0.5% (7/1505 patients) with placebo, whereas the rate of opportunistic infection in patients on anti-integrin therapy was 0.5% (9/1648 patients) versus 0.0% (0/790 patients) with placebo. There were not enough events in pooled data to warrant meaningful statistical analysis of rates of opportunistic infection. Abscess was the most common serious infection reported across all trials of anti-TNF agents. Although numerically more common with active therapy than with placebo (17 occurrences per 1281 patients on therapy versus 8/782 patients on placebo), there were not enough events to warrant meta-analysis. Abscess was not more common in patients with CD on natalizumab versus placebo (2/214 patients had abscess in both study arms). 7 Abscess data were not adequately reported in studies of vedolizumab.
Serious Infections
DISCUSSION
We conducted a systematic review to evaluate the overall risk of developing any infection with contemporary biological agents in IBD. Across all trials with all agents, serious and opportunistic infections were rare. However, we found a statistically significant increased overall infection risk using anti-TNF agents in UC relative to placebo, but a similar significant increase in infection was not seen with anti-integrin agents. The overall infection risk with both classes of agents in the FIGURE 2. A, Forest plots evaluating risk for infection on anti-TNF therapy relative to placebo. Golimumab (PURSUIT-M) and pooled studies of infliximab and adalimumab (ACT 1, ACT 2, and ULTRA 2) had a statistically significant higher risk for infection relative to placebo in treating UC. A similar risk increase was not seen in anti-TNF trials for patients with CD. B, Forest plots evaluating risk for infection on anti-integrin therapy relative to placebo. The risk for infection was not statistically different with anti-integrin agents than placebo. treatment of CD was not statistically different relative to placebo. Infection risk remained uncommon in all analyses, despite statistical significance in treating UC with anti-TNF therapy.
To date, studies evaluating infection risk in the treatment of CD or UC have focused on the specific risks arising directly from opportunistic or serious infections, which appear uncommon in the literature. Opportunistic infection may have a negligible health impact in immunocompetent individuals but can be more severe in an immunosuppressed patient population. 16 Across all trials, although the rate of opportunistic infection in treatment arms of anti-TNF trials was numerically higher than that seen in antiintegrin trials, events of opportunistic infection were too rare to meaningfully assess with statistical analysis with either class of therapy for treating CD or UC in long-term trials. Serious infections were uncommon as well, and the associated risk was not statistically different than with placebo.
These risks for opportunistic and serious infections are well studied in the literature regarding anti-TNF therapy. Two metaanalyses evaluated the risk of serious infection within induction and maintenance anti-TNF trials for CD. 37, 38 In the more recent analysis, 38 the risk for serious infection was small but was greater with anti-TNF therapy (39 infections representing 0.9% occurrence) than with that of placebo (6 infections representing 0.3% occurrence) in pooled induction and maintenance trials (RR ¼ 2.05, 95% CI, 1.10-3.85). However, these data were not stratified by the phase of therapy (induction versus maintenance) or disease (CD versus UC). Ford et al further identified a statistically significant RR for opportunistic infection in trials lasting fewer than 8 weeks (RR ¼ 5.09, 95% CI, 1.13-23.0). Taking into account the findings of our present study which is focused on long-term rather than induction therapy, attention to risk arising from opportunistic or serious infection may be of greater concern during the initial period. More recent data regarding the anti-TNF agent golimumab 35 and with the anti-integrin agents natalizumab 7 and vedolizumab 31, 36 were not available when the prior meta-analyses evaluating infection risk were conducted. 37, 38 After achieving a clinical response with induction therapy, delays in therapy related to more common or mild infections may be of greater concern during long-term therapy with biologics. 18 Attention to overall risk of infection is prudent, given the possibility of developing antibodies and resulting nonresponse or lupus-like reaction associated with long-term therapy 39 and the movement toward earlier use of biological agents in a step-up fashion in the treatment of CD or UC. 1 We identified a statistically significant albeit low overall risk for infection in long-term trials of anti-TNF agents that should be taken into account when treating UC. There was no statistically significant risk for overall infection with anti-TNF therapy for UC or anti-integrin therapy for either disease. Individualized attention to appropriate continuation or delay of therapy in light of infection may help mitigate unnecessary risks associated with a delay in therapy.
Although golimumab was the only therapy associated with a statistically significant risk (albeit infrequent) of any infection in treating UC, our findings may actually represent a minor class effect in treating UC rather than a finding specific to one therapy. Although neither infliximab nor adalimumab were individually associated with a statistically significant risk, the effect size for these agents was similar to the pooled analysis of infliximab and adalimumab, which did result in a statistically significant risk of infection in treating UC.
Our study was limited primarily by the lack of more specific severity data published by study authors. Given the rigor of adverse event reporting requirements in randomized, placebocontrolled clinical trials, even minor infections such as rhinitis are reported. Despite this, analysis of overall infection occurrence in IBD trials remains novel. Published clinical trial data are more likely to focus on opportunistic and serious infections as a way to evaluate the severity of harm because of treatment even as the underlying trials may not have enough power to detect these rare events. By contrast, reports of common infections are more suited to discussions of therapeutic durability and consistency in dosing schedules over longer periods of time. Large-scale endeavors based on a population-wide sample such as the TREAT registry 40 are likely needed to better understand the comparative risk for infection over the long-term with anti-TNF and anti-integrin agents.
There was statistically significant heterogeneity identified in the analysis of infection rates on anti-TNF therapy for CD. The 2 trials reporting the lowest RR of infection (ACCENT 1 and CLASSIC 2) 25, 28 were associated with the lowest rates of concomitant immunomodulatory use. We can hypothesize that this may explain study heterogeneity, although we cannot confirm that infection occurred in these specific patients as only ecologic study-level data are available. The SONIC trial previously evaluated combination biological/immunomodulatory therapy versus biological or immunomodulator monotherapy. 2 Although infection rates were lower with combination therapy in this trial, the trial did not stratify based on induction versus maintenance phases of the study. Further analysis is therefore needed to clarify infection risk with combination therapy versus biological monotherapy.
In summary, we performed the first systematic review and meta-analysis summarizing data from 4984 patients in 13 longterm, placebo-controlled clinical trials to assess the overall infection rate associated with biological agents in treating CD and UC. Although we found that overall infection risk was increased relative to placebo for golimumab and for pooled anti-TNF therapy in treating UC, the rates of overall infection were reassuringly low, and there was no statistical significance of overall infection in the treatment of CD. Opportunistic infection was rare, and there was no increased risk of serious infections in long-term trials for either class of biological therapy or disease indication (CD or UC). Further studies are still needed to evaluate the influence of infection on long-term treatment durability.
